GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beacon Pharmaceuticals PLC (DHA:BEACONPHAR) » Definitions » EV-to-EBITDA

Beacon Pharmaceuticals (DHA:BEACONPHAR) EV-to-EBITDA : 36.10 (As of Apr. 26, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Beacon Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Beacon Pharmaceuticals's enterprise value is BDT53,751 Mil. Beacon Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was BDT1,489 Mil. Therefore, Beacon Pharmaceuticals's EV-to-EBITDA for today is 36.10.

The historical rank and industry rank for Beacon Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

DHA:BEACONPHAR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 15.16   Med: 39.98   Max: 61.61
Current: 36.1

During the past 8 years, the highest EV-to-EBITDA of Beacon Pharmaceuticals was 61.61. The lowest was 15.16. And the median was 39.98.

DHA:BEACONPHAR's EV-to-EBITDA is ranked worse than
86.99% of 707 companies
in the Drug Manufacturers industry
Industry Median: 14.03 vs DHA:BEACONPHAR: 36.10

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), Beacon Pharmaceuticals's stock price is BDT195.70. Beacon Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was BDT2.849. Therefore, Beacon Pharmaceuticals's PE Ratio for today is 68.69.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Beacon Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Beacon Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beacon Pharmaceuticals EV-to-EBITDA Chart

Beacon Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Get a 7-Day Free Trial 16.78 18.45 17.43 30.40 38.32

Beacon Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.47 54.02 38.32 48.09 43.75

Competitive Comparison of Beacon Pharmaceuticals's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Beacon Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beacon Pharmaceuticals's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beacon Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Beacon Pharmaceuticals's EV-to-EBITDA falls into.



Beacon Pharmaceuticals EV-to-EBITDA Calculation

Beacon Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=53750.866/1488.977
=36.10

Beacon Pharmaceuticals's current Enterprise Value is BDT53,751 Mil.
Beacon Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT1,489 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beacon Pharmaceuticals  (DHA:BEACONPHAR) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Beacon Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=195.70/2.849
=68.69

Beacon Pharmaceuticals's share price for today is BDT195.70.
Beacon Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT2.849.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Beacon Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Beacon Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Beacon Pharmaceuticals (DHA:BEACONPHAR) Business Description

Traded in Other Exchanges
N/A
Address
9/B/2, Toyenbee Circular Road, Motijheel C/A, Beacon Business Centre, Dhaka, BGD, 1223
Beacon Pharmaceuticals PLC manufactures and markets pharmaceutical products. Its products are used in various therapeutic areas, such as anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, and muscle relaxants. The company exports its products to Europe, America, Australia, Africa, and Asia. The company's products can be segmented as General, Chronic Care, Oncology, and Biotech products.

Beacon Pharmaceuticals (DHA:BEACONPHAR) Headlines

No Headlines